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Naive and GSTζ-Depleted Rats
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Dichloroacetate (DCA) is a drinking water
disinfectant by-product commonly identiﬁed
in municipal water supplies. Concentrations
of DCA in ﬁnished drinking water have been
reported as high as 133 µg/L (1), although
concentrations < 25 µg/L are more common
(2,3). DCA is a metabolite of certain chlori-
nated industrial solvents and of several phar-
maceuticals (4). DCA has also been used for
decades as an investigational drug to treat
numerous cardiovascular and metabolic dis-
orders in humans, for example, diabetes,
hypercholesterolemia, and amelioration of
lactic acid during liver transplantation (4–6).
Recently, DCA has been used in clinical tri-
als to treat congenital or acquired lactic
acidosis in children (5,7). Human exposure
to DCA ranges from ~1 to 4 µg/kg/day
through consumption of drinking water and
up to 50 mg/kg/day from the use of DCA as
a therapeutic drug (4).
DCA is rapidly and completely absorbed
from the gastrointestinal (GI) tract and is
extensively metabolized both in rodents and
in humans, with glyoxylate, oxalate, glyco-
late, and CO2 being the major metabolites
(8,9). Only a small percentage (< 3%) of the
dose is excreted as the parent compound
(8–10). DCA metabolism occurs primarily in
the liver (11), mediated through a recently
characterized class of glutathione S-trans-
ferase, GSTζ (GSTZ1–1) (12). DCA is also
a mechanism-based inhibitor of GSTζ, and
prolonged exposure to DCA in rodents
causes both reduction in metabolism and
depletion of immunoreactive GSTζ protein
levels from the liver (9,13–15). Thus, in
repeated dosings of DCA, the first dose is
always cleared more rapidly than are subse-
quent doses because of the inactivation of
GSTζ. This has prevented measurement of
oral bioavailability of DCA using a crossover
experimental design because the second dose
is always eliminated more slowly regardless of
the route of administration (16).
DCA has been associated with a number
of toxic effects in animals exposed to high
doses, including testicular abnormalities,
birth defects, and liver cancer (17–20).
Consumption of chlorinated water has been
linked to increased risk for certain cancers in
humans (21) without any speciﬁc correlation
with DCA or other haloacetates. DCA pre-
sents an interesting dilemma for risk asses-
sors because it has a history of safe use as a
therapeutic, but it has created regulatory
concern because of its carcinogenicity in ani-
mals. The U.S. Environmental Protection
Agency (EPA) has classiﬁed DCA as a likely
human carcinogen based on the hepatocar-
cinogenic effects observed in rodents (22).
Because of the prevalence of halogenated
acetic acids in finished drinking water and
their possible link to human cancer, the U.S.
EPA has set standards permitting a com-
bined total of 60 µg/L of ﬁve common halo-
genated acetic acids (HAA5) in drinking
water. The goal of the U.S. EPA is the vir-
tual elimination of DCA from drinking
water under stage I regulations (22).
Previous pharmacokinetic studies of
DCA have focused on therapeutic (i.e., mil-
ligram per kilogram) doses. Also, the effects
of GSTζ depletion on DCA disposition have
not been studied in detail. Therefore, we
designed this study to determine the phar-
macokinetics and oral bioavailability of
DCA in cohorts of naive and GSTζ-
depleted rats using a range of doses down to
50 µg/kg. We also compared the in vitro
metabolism of DCA in human liver cytosol
with cytosol obtained from naive and GSTζ-
depleted rats. We made this comparison to
aid in determining the appropriateness of
using the GSTζ-depleted rat model for
understanding low-dose pharmacokinetics of
haloacetates in humans.
Materials and Methods
Chemicals. We purchased DCA (> 99%
pure as free acid) from Fluka Chemical
Corp. (Milwaukee, WI). Reagent-grade
methyl-tert-butyl ether (MTBE) was pur-
chased from Fisher Scientific (Pittsburgh,
PA). We prepared diazomethane from 
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We studied the pharmacokinetics of dichloroacetate (DCA) in naive rats and rats depleted of glu-
tathione S-transferase-zeta (GSTζ), at doses approaching human daily exposure levels. We also
compared in vitro metabolism of DCA by rat and human liver cytosol. Jugular vein-cannulated
male Fischer-344 rats received graded doses of DCA ranging from 0.05 to 20 mg/kg (intra-
venously or by gavage), and we collected time-course blood samples from the cannulas. GSTζ
activity was depleted by exposing rats to 0.2 g/L DCA in drinking water for 7 days before initia-
tion of pharmacokinetic studies. Elimination of DCA by naive rats was so rapid that only 1–20
mg/kg intravenous and 5 and 20 mg/kg gavage doses provided plasma concentrations above the
method detection limit of 6 ng/mL. GSTζ depletion slowed DCA elimination from plasma,
allowing kinetic analysis of doses as low as 0.05 mg/kg. DCA elimination was strongly dose
dependent in the naive rats, with total body clearance declining with increasing dose. In the
GSTζ-depleted rats, the pharmacokinetics became linear at doses ≤ 1 mg/kg. Virtually all of the
dose was eliminated through metabolic clearance; the rate of urinary elimination was < 1
mL/hr/kg. At higher oral doses (≥ 5 mg/kg in GSTζ-depleted and 20 mg/kg in naive rats), sec-
ondary peaks in the plasma concentration appeared long after the completion of the initial
absorption phase. Oral bioavailability of DCA was 0–13% in naive and 14–75% in GSTζ-
depleted rats. Oral bioavailability of DCA in humans through consumption of drinking water was
predicted to be very low and < 1%. The use of the GSTζ-depleted rat as a model for assessing the
kinetics of DCA in humans is supported by the similarity in pharmacokinetic parameter estimates
and rate of in vitro metabolism of DCA by human and GSTζ-depleted rat liver cytosol. Key
words: animal study, dichloroacetic acid, drinking water disinfection by-products, halogenated
acetic acids, human risk assessment, human in vitro metabolism, low-dose pharmacokinetics, oral
bioavailability, rat in vitro metabolism, toxicology. Environ Health Perspect 110:757–763 (2002).
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Aldrich Technical Information Bulletin AL
121 (23). All other chemicals were of the
purest grade available and were obtained
from standard sources. All dosing solutions
were prepared in 0.9% (w/v) NaCl and pH
adjusted to 7.0 with NaOH.
Animals and treatment. The Institutional
Animal Care and Use Committee of Battelle,
Pacific Northwest National Laboratory
approved the animal care and experimental
protocols, and animal care and treatment was
conducted in accordance with their estab-
lished guidelines. 
For pharmacokinetic experiments, we
purchased 8- to 10-week-old male Fischer
344 rats (185 ± 29 g body weight, mean ±
SD; n = 41 naive rats) fitted with a jugular
vein cannula from Taconic Laboratories
(Germantown, NY). We also purchased 6
noncannulated rats from Charles River
Laboratories (Raleigh, NC) for the prepara-
tion of liver cytosol. We housed jugular
vein–cannulated rats individually, whereas we
housed three noncannulated rats per cage.
Each cage contained wood-chip bedding and
stainless steel wire tops, and rats were housed
under standard conditions (22°C, 40–60%
relative humidity, 12-hr light/dark cycle). We
allowed rats a minimum of 48 hr for recovery
from transport before use in experiments.
Initially, rats were provided with deion-
ized water and Purina rat chow (St Louis,
MO) ad libitum. We used deionized water
throughout the experiments to avoid
unwanted exposure to haloacetates, which
can be present in drinking water sources and
may cause some inactivation of GSTζ.
Animals were fasted overnight before the
administration of DCA. We dosed naive ani-
mals intravenously (iv) or by gavage
(4–6/dose group) with 1, 5, or 20 mg/kg
DCA and housed them in polycarbonate
metabolism cages. After the initial dosing
experiments, we then provided the same
individual rats with 0.2 g/L DCA in their
drinking water for 7 days to deplete/inacti-
vate GSTζ activity (henceforth GSTζ
depleted). We also pretreated one group of
three noncannulated rats for 7 days with 0.2
g/L DCA in their drinking water to deplete
GSTζ. We then switched the GSTζ-depleted
animals to non-DCA–fortified water
overnight (16 hr) to allow residual DCA to
be cleared from the body. This treatment
protocol was previously shown to reduce
GSTζ activity by > 90% in rat liver cytosol
(24), and the experimental results presented
in this study further conﬁrm this ﬁnding. We
then dosed GSTζ-depleted rats (4–6 per dose
group) iv with 0.05, 0.25, 1, 5, or 20 mg/kg
or gavaged them with 0.25, 1, 5, or 20
mg/kg DCA. We gavaged two additional
GSTζ-depleted rats with 100 mg/kg DCA to
estimate oral bioavailability at this highest
dose using earlier reported iv data of
Gonzalez-Leon et al. (9). We administered
dosing solutions at a volume of 1 mL/kg.
Sample collection and analysis. We col-
lected serial blood samples (0.075–0.125 mL)
from individual rats through the jugular vein
cannula using a 1-mL syringe coated with
sodium heparin. After each blood sample, we
flushed the cannula with ~0.2 mL of
heparinized saline (40 U/mL heparin). We
obtained plasma by centrifugation, mixed it
with 0.2 mL of ice-cold 0.1 M sodium acetate
buffer (pH 5.2), and stored the plasma at
–20°C until analysis. We determined actual
plasma volumes gravimetrically using tared
vials and assuming plasma density of 1.0. A
typical blood sampling schedule after iv dos-
ing was 0, 3, 6, 10, 15, 20, 25, and 30 min
and variously thereafter up to 24 hr, depend-
ing on the dose and pretreatment. For orally
dosed animals, we added an additional 1-min
sample. Sampling continued until plasma
concentrations were expected to have declined
below the method detection limit (MDL) for
DCA. We calculated the MDL as described
by Glaser et al. (25) using nine replicate
plasma samples. The MDL for DCA in naive
and GSTζ-depleted rat plasma was 6 and 10
ng/mL, respectively. The MDL for plasma
removed from GSTζ rats was slightly higher
because of elevated background levels. We
collected urine from each rat for 24 hr, mixed
an aliquot with sodium acetate buffer, and
stored the samples at –20°C until analysis.
For experiments measuring diurnal
changes in plasma DCA levels, we provided
four rats with 0.2 g/L DCA water and col-
lected time-course blood samples up to 24
hr, after which we gave animals non-DCA
water and collected the last blood samples 11
hr later. We allowed animals used in the
kinetic experiments an additional 5 hr on
non-DCA water (16 hr total depuration
before administering DCA). This additional
time was to ensure that residual DCA con-
centration in plasma approached back-
ground values without signiﬁcant resynthesis
of the GSTζ enzyme (26). We veriﬁed resid-
ual concentration after depuration by mea-
suring DCA levels in plasma collected before
dosing (time 0) and comparing them with
levels in non-DCA treated rats.
We analyzed all plasma samples antici-
pated to contain > 100 ng DCA using a pre-
viously described method (27). Briefly, we
added 0.025 mL (0.2 µg) internal standard
(dibromoacetic acid) to samples (plasma and
urine), acidified them by adding 0.025 mL
50% sulfuric acid (v/v), and extracted in vari-
ous volumes (0.2–1.0 mL) of MTBE
depending on the dose and sampling time.
We extracted samples anticipated to contain
< 100 ng DCA in 0.2 mL MTBE. We then
concentrated the extracted DCA by reducing
the volume of MTBE to 0.01–0.02 mL
under a gentle stream of N2. We converted
the free acid to the methyl ester by adding
0.01–0.02 mL ethereal diazomethane (previ-
ously diluted 1:10 with MTBE). We then
analyzed samples by gas chromatography
with electron-capture detection (Hewlett-
Packard 5890-Series II, Avondale, PA). The
additional preconcentration step increased
the MDL for DCA by 50- to 75-fold when
compared to our previous method. We deter-
mined stability of DCA in urine by fortifying
freshly collected urine from a naive rat with
DCA (10 µg); the fortified samples were
either stored at –20°C or left at room tem-
perature for 24 hr. We then analyzed DCA
as described above and compared the results.
Degradation of DCA in urine was negligible;
> 90% could be recovered from urinary sam-
ples left at room temperature for 24 hr.
Kinetic analysis. The methods we used
to analyze the concentration–time proﬁles of
DCA were similar to those used by Schultz
et al. (27). Brieﬂy, we analyzed the individ-
ual plasma profiles after both iv and oral
administration by noncompartmental meth-
ods to obtain estimates of total body clear-
ance, apparent volume of distribution at
steady state (Clb, Vss, for iv doses only), and
the mean residence time (MRT) using the
standard equations for these parameters that
are incorporated into the WinNonlin
program (Pharsight Corp., Cary, NC).
WinNonlin calculates the area under the
curve (AUC0→∞) by the linear trapezoidal
method with the terminal portion of the
curve extrapolated from time 0 to inﬁnity by
Cp,t/β, where Cp,t is the concentration of
DCA in plasma at the last observation and β
is the slope of the terminal phase determined
by linear regression. WinNonlin calculated
the elimination half-life (t1/2,β) as 0.693/β.
We calculated renal clearance as Clr =
Χu0→24/AUC0→24, where Χu0→24 is the total
amount of DCA recovered in the urine after
24 hr. We also report the observed peak
plasma concentration of DCA (Cmax) and the
time of its occurrence (Tmax) after oral dos-
ing. We calculated the oral bioavailability
from the ratios of the average values for
AUC0→∞ for the oral and iv doses, and calcu-
lated the mean absorption time (MAT) as the
difference between the MRToral and MRTiv.
Preparation of liver cytosol. We prepared
rat liver cytosol from male F-344 rats (8–10
weeks old; n = 3 naive and 3 GSTζ depleted)
by differential centrifugation as described by
Okita and Okita (28). We purchased two
human liver sections and a pooled S-9 frac-
tion obtained from 10 donors from the
International Institute for the Advancement
of Medicine (Exton, PA). The human liver
section designated Human 1 was from a 
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height, 1.78 m) who died of cardiopul-
monary arrest; the Human 2 liver section was
from a 68-year-old white female (body
weight 73 kg; height 1.63 m) who died of a
brain stem infarction. The pooled S9 desig-
nated Human Pooled was prepared from
liver tissue obtained from 10 white male
donors of 8, 40, 40, 48, 51, 52, 53, 58, 63,
and 64 years of age, who died of cardiovascu-
lar disease, brain hemorrhage, anoxia, anoxia,
head injury, anoxia, stroke, head injury,
anoxia, and head injury, respectively. We
prepared cytosol from the liver sections as
described for rats by Okita and Okita (28)
and from pooled human S-9 by centrifuga-
tion at 100,000 × g for 1 hr. Liver sections
had been perfused with University of
Wisconsin medium and contained viable
hepatocytes. We stored aliquots of cytosol at
–70°C until use, and determined protein
concentrations as described by Bradford (29).
DCA depletion in cytosol and determi-
nation of intrinsic metabolic clearance. We
measured the depletion of added DCA using
rat and human hepatic cytosol. Incubation
mixtures consisted of 1–4 mg/mL protein,
0.1 M phosphate buffer (pH 7.4), and 1.4
mM glutathione in a final incubation vol-
ume of 3 mL. We preincubated solutions for
2 min at 37°C in a shaking water bath and
started the reaction by adding 0.025 mg
DCA prepared in 0.1 M phosphate buffer
(pH 7.4). We removed a 0.15-mL aliquot
from each incubate at various times (0.2–60
min) and added it to a mixture of 0.25 mL
0.1 M sodium acetate and 0.05 mL of 50%
H2SO4 to stop the reactions. We added
internal standard to each aliquot and
extracted and analyzed DCA as described
above. We plotted the loss of DCA against
time and calculated AUC as described above.
We calculated the intrinsic metabolic clear-
ance (Clint) by dividing the initial amounts
of DCA (at time 0.2 min) in the incubation
medium with that of the AUC values (30).
We scaled up the Clint to a whole animal/
human by calculating the amount of cytoso-
lic protein per gram of liver for rat and
humans. For rats, we used measured liver and
body weights. For humans, we assumed liver
to be 2.5% of the body weight as reported by
Davies and Morris (31). We calculated the
hepatic clearance as
[1]
where Qh is the liver blood ﬂow and fu is the
unbound fraction of DCA in plasma. We
assumed the total cardiac output for F-344
rats was 17.38 L/hr/kg [from Hachamovitch
et al. (32)]. We calculated the Qh to be 3.13
L/hr/kg by adjusting for the percentage
blood flow (18%) to the liver (33). For
humans, we assumed total cardiac output to
be 312 L/hr and liver blood ﬂow to be 22%
of this value [from Astrand (34) and
Williams and Leggett (35), respectively].
The calculated Qh for a 70 kg human was
1.01 L/hr/kg. The unbound fraction for
DCA in rat plasma was 0.94 ± 0.07 (27) and
we assumed it to be the same for humans.
Statistics. We assessed signiﬁcant differ-
ences between pharmacokinetic parameter
estimates from the different treatment groups
by Student’s t-test. We also performed analy-
sis of variance on the individual Clb values to
determine if they were signiﬁcantly different.
We considered a p-value of ≤ 0.05 to be sta-
tistically signiﬁcant.
Results
Plasma DCA levels while receiving DCA
treatment. To study the pharmacokinetics of
DCA in rats with reduced metabolism, we
exposed animals to DCA (0.2 g/L) in drink-
ing water for 7 days to effectively deplete the
GSTζ enzyme. Periodically, we monitored
consumption of water and plasma DCA lev-
els to verify concentrations during the expo-
sure and residual levels after 16 hr of
washout. The average consumption of water
by rats was 80 mL/kg/day, corresponding to
a daily DCA dose of around 16 mg/kg.
Figure 1 shows the diurnal plasma levels of
DCA in rats provided with 0.2 g/L DCA-
fortified water. DCA plasma levels were
much higher during the dark cycle. We
observed peak plasma levels at 500 hr (1 hr
before lights on), which declined thereafter.
The levels of DCA in plasma started to
climb again 2 hr before the lights were
turned off, corresponding to the increased
activity (drinking/eating). We found the
minimum plasma concentration of DCA at
1600 hr. During an 11-hr depuration period
after removal of DCA-fortified drinking
water, plasma levels of DCA rapidly dropped
to 10 ± 2 ng/mL (Figure 1). We provided
animals used in kinetic experiments an addi-
tional 5 hr of washout (16 hr total depura-
tion) that allowed DCA plasma levels to fall
below 10 ng/mL.
Intravenous administration. Figure 2
shows the mean (± SE) plasma concentra-
tion–time proﬁles. The decline of DCA from
plasma of naive rats was so rapid that the low-
est dose that could be used for kinetic analysis
was 1 mg/kg, which had a plasma elimination
half-life of approximately 4 min (Figure 2A,
Table 1). In contrast, elimination of DCA
from the plasma of GSTζ-depleted rats was
much slower, allowing kinetic analysis of doses
as low as 0.05 mg/kg (Figure 2B inset). Visual
inspection of the plasma concentration–time
proﬁles and the pharmacokinetic parameters
presented in Table 1 for the naive rats indicate
that DCA declined from plasma in a monoex-
ponential manner. Decline of DCA from
plasma of the GSTζ-depleted rats became
biexponential at the higher doses (Figure 2B).
Table 1 summarizes the kinetic analysis
of DCA for the naive and GSTζ-depleted
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Figure 1. Diurnal plasma concentration proﬁle of DCA in rats administered 0.2 g/L DCA in drinking water
and its elimination upon removal of the DCA-fortiﬁed water. Each point indicates mean ± SE (n = 4).
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Light /dark cyclerats. In general, the kinetics of DCA were sim-
ilar to previous descriptions (9,27): rapid elim-
ination by the naive rats with GSTζ depletion
causing an increase in t1/2,β and MRT and a
decrease in the total body clearance (Clb).
DCA was essentially eliminated through
metabolism by both naive and GSTζ-depleted
rats. The renal clearance of DCA accounted
for < 1% of the total body clearance at most
doses (Table 1). The steady-state volume of
distribution (Vss) did not appear to be affected
by GSTζ depletion or with dose, ranging non-
systematically between 223 and 618 mL/kg
(Table 1). The main pharmacokinetic parame-
ter that was affected by treatment and dose
was Clb. In naive rats, we observed nonlinear
kinetics throughout the dosing regimen (Table
1). In GSTζ-depleted rats, however, the phar-
macokinetics became linear at doses < 1
mg/kg; Clbwas not different (p ≥ 0.4) at these
lower doses (Table 1).
Oral administration. The average
plasma concentration–time proﬁles of DCA
after gavage dosing are presented in Figure 3
and a summary of the pharmacokinetic para-
meters is presented in Table 2. DCA was
rapidly absorbed after oral dosing and
detected in plasma within 1 min after dosing
(Figure 3). In naive rats, the greater capacity
for metabolism limited the doses that could
be used. Pilot experiments using a dose of 1
mg/kg failed to detect plasma concentrations
above the MDL (6 ng/mL) because DCA
was apparently completely metabolized
before reaching the general circulation
(Table 2). The decline in the plasma concen-
tration of DCA after the initial peak
appeared to be monoexponential at lower
doses (5 mg/kg in the naive and ≤ 1 mg/kg
in the GSTζ-depleted rats; Figure 3). At
higher doses (20 mg/kg in naive rats and ≥ 5
mg/kg in GSTζ-depleted rats), DCA dis-
played complex plasma concentration–time
profiles, with secondary plasma peaks
appearing between 4–8 hr after dosing, long
after completion of the initial absorption
phase (Figure 3). This observation is consis-
tent with a previous report of the absorption
of DCA in naive rats gavaged with a 100
mg/kg dose (27). In GSTζ-depleted rats, the
secondary plasma peak was less apparent at
the highest gavaged dose of 20 mg/kg
(Figure 3B). This observation implies that a
complex dose–response relationship exists in
GSTζ-depleted rats between the oral dose
and appearance of the secondary plasma
peaks, with both very low and high doses
displaying a less pronounced secondary peak.
This relationship may also apply to naive
rats, although the high dose needed to
obscure the secondary peak is apparently
> 100 mg/kg.
The complex plasma concentration–time
proﬁle at the higher doses contributed to the
disproportionate increase in the AUC0→∞
between the doses (Table 2). Maximum
plasma concentrations were reached within
5–10 min in naive and 8–45 min in GSTζ-
depleted rats (Table 2, Figure 3). In the
GSTζ-depleted rats, peak plasma concentra-
tions (Cmax) were 4- to 6-fold higher than in
the naive rats. The higher Cmax and longer
MRT in GSTζ-depleted rats was also
reﬂected by a 22- to 56-fold increase in the
AUC0→∞ (Table 2). The MAT in both
naive and GSTζ-depleted rats was increased
in a dose dependent manner.
The oral bioavailability of DCA was sig-
niﬁcantly reduced in naive rats. At doses of 5
and 20 mg/kg, bioavailability was only 10%
and 13%, respectively. At a higher dose of
100 mg/kg, the oral bioavailability reached
81% (Table 2). Bioavailability at 1 mg/kg
could not be calculated because of the lack
of detectable concentrations of DCA in
plasma. In GSTζ-depleted rats, the oral
bioavailability was 14%, 29%, 31%, and
75% at the 0.25, 1, 5, and 20 mg/kg doses,
respectively, and became 100% at 100
mg/kg (Table 2).
Correlation between dose and kinetic
parameters. Figure 4 presents the correlation
between dose and percent oral bioavailabil-
ity. The relationship between dose and oral
bioavailability of DCA for the GSTζ-
depleted rats was best defined by saturable
mechanism using a hyperbolic distribution
with a correlation coefficient (r 2) of 0.90
(Figure 4). The relationship between dose
and oral bioavailability for the naive rats was
less clear, and Figure 4 shows only the
observed data. 
Cytosolic metabolism of DCA. The results
of in vitro experiments using liver cytosol
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Table 1. Pharmacokinetic parameters of DCA after iv administration of a range of doses in naive and
GSTζ-depleted adult male F-344 rats.
Dose AUC0→∞ Vss Clb MRT t1/2
(mg/kg) No. (µg/mL/hr) (mL/kg) (mL/hr/kg)a (hr) (hr)
Naive rats
15 0.15 ± 0.01 508 ± 68.6 6,554 ± 356 0.07 ± 0.01 0.07 ± 0.001
56 1.24 ± 0.05 415 ± 47.2 5,265 ± 636 0.08 ± 0.01 0.08 ± 0.003
20 5 13.8 ± 0.85 223 ± 111.0 1,571 ± 97 0.14 ± 0.01 0.15 ± 0.01
100b,c 5 433 ± 233 618 ± 319.0 267 ± 105 2.10 ± 0.86 2.4 ± 0.15
GSTζ-depleted rats
0.05 4 0.04 ± 0.01 277 ± 33.4 1,326 ± 342d 0.23 ± 0.05 0.19 ± 0.05
0.25 6 0.15 ± 0.03 454 ± 57.3 1,816 ± 288d 0.18 ± 0.03 0.17 ± 0.02
15 0.61 ± 0.02 261 ± 13.6 1,640 ± 57d 0.19 ± 0.04 0.20 ± 0.05
54 8.21 ± 0.50 392 ± 31.4 614 ± 39 0.64 ± 0.04 0.50 ± 0.03
20 4 136.6 ± 3.4 513 ± 18.5 168 ± 22 3.45 ± 0.09 1.81 ± 0.09
100c 62 ,410 ± 406 582 ± 146 43 ± 8 NR 10.8 ± 2.0
NR, not reported.
aClrenal was < 0.7 mL/hr with the exception of 100 mg/kg (2.9 ± 0.5 mL/hr for naive and 8.9 ± 3.3 mL/hr for GSTζ-depleted)
doses. bData from Schultz et al. (27). cData from Gonzalez-Leon et al. (9). dNot signiﬁcantly different from each other: p ≥ 0.4.
Figure 2. The plasma concentration–time profiles of DCA after iv administration of a series of doses of
1–20 mg/kg to naive (A) and 0.05–20 mg/kg to GSTζ-depleted rats (B). Data shown are mean ± SE (n =
4–6). Error bars that fit within the data point are not shown. To avoid crowding of data points on the y-
axis, the line was slightly shifted to the left.
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Time (hr)were consistent with in vivo kinetic analysis;
that is, GSTζ depletion significantly
decreases DCA metabolism/elimination. The
rate of DCA metabolism by naive rat cytosol
was signiﬁcantly faster (p < 0.01) than that in
the GSTζ-depleted rats (Figure 5). The
intrinsic metabolic clearance (Clint) of DCA
by the human liver cytosol closely resembled
that in GSTζ-depleted rats (Figure 5) and
was not statistically different (p > 0.3). Table
3 presents the predicted hepatic clearance
(Clh) and extraction efﬁciency (Ess) of DCA
by rats and humans. We derived these pre-
dicted values using in vitro Clint of DCA by
the rat and human liver cytosol. The Clh and
Ess of DCA by naive rats was 3-fold higher
than that by the GSTζ-depleted rats. We
predict humans to have somewhat lower Clh
and similar Ess of DCA compared with
GSTζ-depleted rats (Table 3).
Discussion
The results of this study demonstrate that
elimination of DCA in naive rats exhibits
nonlinear behavior at all doses that allowed
pharmacokinetic analysis. The Clb continued
to increase at lower iv doses and exceeded 6.5
L/hr/kg at the 1 mg/kg dose. The cardiac out-
put in F-344 rats of body size comparable to
those used in this study has been reported to
be 17.38 L/hr/kg (32). Therefore, the clear-
ance of DCA in naive rats at low doses is at
least 38% of cardiac output, which would
exceed liver blood ﬂow and implies extensive
extrahepatic elimination of DCA occurs. In
contrast, the pharmacokinetics of DCA in
GSTζ-depleted rats becomes linear at doses
≤ 1 mg/kg (Table 1); the Clb ranged between
1.33 and 1.82 L/hr/kg after iv doses of
0.05–1 mg/kg. Assuming liver blood ﬂow is
3.13L/hr/kg (i.e., fraction of cardiac output to
the liver is 0.18) (33) and liver metabolism
accounts for the bulk of DCA elimination (in
GSTζ-depleted rats), DCA clearance appears
to correspond to 42–58% of liver blood ﬂow.
This finding indicates that DCA is moder-
ately extracted by liver under linear kinetics
by GSTζ-depleted rats. At higher doses,
metabolism becomes saturated, and liver
extraction decreases.
The complex plasma concentration–time
profiles of DCA observed after some oral
doses (Figure 3) agreed with those in an ear-
lier report (27). The extent of the secondary
peaks appears to be reduced at lower doses
and was absent after doses that only pro-
duced detectable levels of DCA until 4 hr
after dosing (5 and 20 mg/kg in this study).
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Table 2. Pharmacokinetic parameters of DCA after oral administration of a range of doses in naive and
GSTζ-depleted adult male F-344 rats.a
Dose AUC0→∞ Tmax Cmax MRT MAT Bioavailability
(mg/kg) No. (µg/mL/hr) (hr) (µg) (hr) (hr) (%)
Naive rats
13 B D BD BD 0 0 0
56 0.12 ± 0.01 0.09 ± 0.02 0.36 ± 0.07 0.28 ± 0.04 0.20 9.68
20 6 1.82 ± 0.10 0.17 ± 0.01 2.91 ± 0.24 1.70 ± 0.49 1.56 13.20
50b 4 11.7 ± 1.68 0.27 ± 0.04 9.29 ± 1.87 NR NR ND
100c 5 218 ± 74.5 8.0 27.4 6.70 ± 1.44  4.5 80.93
GSTζ-depleted rats
0.25 6 0.02 ± 0.01 0.13 ± 0.01 0.08 ± 0.01 0.39 ± 0.03 0.19 14.0
14 0.18 ± 0.03 0.12 ± 0.02 0.26 ± 0.01 1.05 ± 0.07 0.86 29.4
54 2.58 ± 1.05 0.25 ± 0.03 1.66 ± 0.31 1.80 ± 0.19 1.16 31.4
20 4 103 ± 14.0 0.75 ± 0.25 17.0 ± 1.90 4.63 ± 0.69 1.18 75.0
100 2 2,730 3.32 151 12.5 ND 100
Abbreviations: BD, below detection (< MDL); MAT, mean, absorption, time; ND, not determined; NR, not reported.
aClrenal was < 0.8 mL/hr with the exception of 100 mg/kg dose, where it was 2.32 mL/hr. Clrenal for 50 mg/kg has not been
reported by the James et al. (10). bData from James et al. (10). cData from Schultz et al. (27).
Figure 3. The plasma concentration–time profiles of DCA after oral administration of 5 and 20 mg/kg to
naive rats (A) and a series of doses ranging from 0.25 to 20 mg/kg to GSTζ-depleted rats (B). Data shown
are mean ± SE (n = 4–6). Error bars that ﬁt within the data point are not shown. To avoid crowding of data
points on the y-axis, the line was slightly shifted to the left.
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*Also, the timing of the secondary peak does
not appear to be affected by GSTζ deple-
tion. Appearance of the secondary peak is
not associated with enterohepatic circula-
tion because DCA does not undergo
extensive biliary secretion (27). Another
interesting observation from our previous
haloacetate study was that only di-substi-
tuted chlorohaloacetates and bromohaloac-
etates exhibit secondary peaks in the plasma
profiles, whereas the tri-substituted haloac-
etates do not (27). Thus, dihaloacetates
such as DCA possess specific structural
characteristics that promote discontinuous
absorption. Proposed mechanisms to
explain discontinuous absorption include
(among others) variable gastric emptying
and GI region-dependent absorption
(36,37). In the present and previous haloac-
etate study (27), oral dosing experiments
were performed on overnight-fasted rats,
which should preclude variable gastric emp-
tying as a contributing factor. We hypothe-
size that DCA absorption is region
dependent, as characterized by rapid absorp-
tion from the stomach and perhaps the
upper regions of the small intestine (i.e.,
duodenum and/or jejunum) and reduced
absorption in the ileum region followed by
increased absorption from the colorectal
region, which then increases absorption in
the lower GI tract, causing the secondary or
multiple plasma maxima. The specific
mechanism that would reduce absorption in
the upper GI tract is unknown at present
but warrants further investigation because of
the potential importance in controlling
DCA absorption and bioavailability.
Comparison of clinical pharmacokinetic
data for DCA with the results of the present
study indicates that DCA elimination in
GSTζ-depleted rats is similar to humans.
Table 4 shows the proﬁle of kinetic parame-
ters (Vd or Vss, Clb, and t1/2,β) obtained from
the literature for a range of iv doses in
human subjects for comparison with the
results obtained in rats (Table 1). In general,
the pharmacokinetic behavior of DCA in
humans shows a trend similar to that
observed in rats, with the Clb decreasing
with increasing dose over a dose range of
10–100 mg/kg (Table 4). Also consistent
with ﬁndings in F-344 rats was the lack of a
dose effect on the apparent volume of distri-
bution (Vd). Importantly, the Clb deter-
mined from GSTζ-depleted rats after iv
dosing closely resembles values reported for
humans (Table 4). This observation suggests
that the capacity to eliminate DCA is similar
in humans and GSTζ-depleted rats. Based
on the threshold dose for linear kinetics
observed in GSTζ-depleted rats (Tables 1
and 4), the pharmacokinetics of DCA in
humans are predicted to become linear at
lower doses (10- to 15-fold lower) than pre-
viously tested in clinical studies. Prediction
of DCA pharmacokinetics in humans based
on the results obtained from the GSTζ-
depleted rat model is further validated by the
similar in vitro intrinsic metabolic clearance
of DCA by human and GSTζ-depleted rat
liver cytosol (Figure 5).
To accurately assess the risk from drink-
ing water exposure to DCA, we must have
some knowledge of the bioavailability of
DCA. However, it is currently impossible to
measure oral bioavailability directly at con-
centrations encountered in drinking water
because the resultant plasma concentrations
are below analytical detection limits. As an
alternative, oral bioavailability can be esti-
mated from the relationship shown in Figure
4 for GSTζ-depleted rats. By extrapolating
down to a dose of 4 µg/kg, we estimate the
oral bioavailability of DCA to be approxi-
mately 0.05%. It appears from the results of
this study that the systemic bioavailability of
DCA at low exposure rates is quite low and
perhaps is minimal to humans consuming
drinking water at reported levels of DCA.
In summary, the bioavailability of DCA
to humans at dose rates received from drink-
ing water is predicted to approach zero, and
further regulation of DCA in drinking water
may not be necessary. Additional factors that
support this conclusion include the following:
a) oral ingestion is the primary exposure route
because nonvolatile DCA is not absorbed
through skin (38); and b) tumorigenicity data
in rodents indicate that only relatively high
drinking water doses (≥ 40 mg/kg/day) cause
liver cancer (18). A no observed effects level
(NOEL) for DCA has been reported to be
3–8 mg/kg/day in rats (18). In contrast,
human daily exposure rates to DCA from
drinking water are more than 1,000 times
lower than this value (39).
The use of high doses in rodent bioassays
is frequently justified by the more rapid
pharmacokinetic behavior that is observed in
rodents compared to humans. For many
potential human toxicants, blood levels in
rodents and humans may be similar despite
100-fold differences in exposure rate (40).
However, in the case of DCA, exposure of
rodents to high levels depletes GSTζ activ-
ity, causing the pharmacokinetics in rats to
become comparable to humans (Tables 3
and 4). Future regulatory action toward
DCA needs to consider the low or negligible
bioavailability of DCA from drinking water
combined with the high blood levels of
DCA that are produced during rodent bioas-
says (e.g., Figure 1).
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